Evidence map›Paper›PMID 25802006›Full record

ArticleProtoplasma2016

Vitamin U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties.

Selda Gezginci-Oktayoglu, Ismet Burcu Turkyilmaz, Merve Ercin, Refiye Yanardag, Sehnaz Bolkent

Abstract read
PubMed Publisher
In one paragraph

Article in Protoplasma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Vitamin U Attenuates Acute Aflatoxin BVeterinary sciences · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Production of S-methyl-methionine using engineered Saccharomyces cerevisiae sake K6.Journal of industrial microbiology & biotechnology · 2023
    Article
  10. A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Selda Gezginci-OktayogluFaculty of Science, Department of Biology, Istanbul University, 34134, Vezneciler, Istanbul, Turkey. selgez@istanbul.edu.tr.
Ismet Burcu TurkyilmazFaculty of Engineering, Department of Chemistry, Istanbul University, 34320, Avcilar, Istanbul, Turkey.
Merve ErcinFaculty of Science, Department of Biology, Istanbul University, 34134, Vezneciler, Istanbul, Turkey.
Refiye YanardagFaculty of Engineering, Department of Chemistry, Istanbul University, 34320, Avcilar, Istanbul, Turkey.
Sehnaz BolkentFaculty of Science, Department of Biology, Istanbul University, 34134, Vezneciler, Istanbul, Turkey.
Istanbul University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of present study was to investigate the effect of vitamin U (vit U, S-methylmethionine) on oxidative stress, inflammation, and fibrosis within the context of valproic acid (VPA)-induced renal damage. In this study, female Sprague Dawley rats were randomly divided into four groups: Group I consisted of intact animals, group II was given vit U (50 mg/kg/day, by gavage), group III was given VPA (500 mg/kg/day, intraperitonally), and group IV was given VPA + vit U. The animals were treated by vit U 1 h prior to treatment with VPA every day for 15 days. The following results were obtained in vit U + VPA-treated rats: (i) the protective effect of vit U on renal damage was shown by a significant decrease in histopathological changes and an increase in Na(+)/K(+)-ATPase activity; (ii) anti-oxidant property of vit U was demonstrated by a decrease in malondialdehyde levels and xanthine oxidase activity and an increase in glutathione levels, catalase and superoxide dismutase activities; (iii) anti-inflammatory property of vit U was demonstrated by a decrease in tumor necrosis factor-α, interleukin-1β, monocyte chemoattractant protein-1 levels, and adenosine deaminase activity; (iv) anti-fibrotic effect of vit U was shown by a decrease in transforming growth factor-β, collagen-1 levels, and arginase activity. Collectively, these data show that VPA is a promoter of inflammation, oxidative stress, and fibrosis which resulted in renal damage. Vit U can be proposed as a potential candidate for preventing renal damage which arose during the therapeutic usage of VPA.

Indexed as

AnimalsAnti-Inflammatory AgentsAntioxidantsBlotting, WesternCatalaseCollagen Type ICreatinineFemaleFibrosisGlutathioneGlutathione TransferaseImmunoblottingInflammationKidneyLipid PeroxidationOxidative StressAnti-Inflammatory AgentsAntioxidantsCatalaseCollagen Type ICreatinineGlutathioneGlutathione TransferaseSuperoxide DismutaseTransforming Growth Factor beta1UreaValproic AcidVitamin UFibrosisInflammationKidneyOxidative damageValproic acidVitamin U

Identifiers

PMID25802006
OpenAlexW2038300464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.